ImOl-200

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameImOl-200
Drug Alias NameRNA based immunotherapy (Rigontec)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRetinoic acid-inducible gene I stimulants
TargetsRetinoic acid-inducible gene I
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRigontec Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRigontec Gmbh
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A